Clostridium difficile infection: new developments in epidemiology and pathogenesis

Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.

[1]  S. Coffin,et al.  Epidemiological Features of Clostridium difficile-Associated Disease Among Inpatients at Children's Hospitals in the United States, 2001–2006 , 2008, Pediatrics.

[2]  M. Wilcox,et al.  A case-control study of community-associated Clostridium difficile infection. , 2008, The Journal of antimicrobial chemotherapy.

[3]  J. Weese,et al.  Clostridium difficile PCR Ribotypes in Calves, Canada , 2006, Emerging infectious diseases.

[4]  N. Fairweather,et al.  Revised nomenclature of Clostridium difficile toxins and associated genes. , 2005, Journal of medical microbiology.

[5]  D. Gerding,et al.  Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters. , 2006, The Journal of infectious diseases.

[6]  T. Leet,et al.  Environmental control to reduce transmission of Clostridium difficile. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Rupnik.  Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. , 2008, FEMS microbiology reviews.

[8]  O. Lesur,et al.  Impact of Emergency Colectomy on Survival of Patients With Fulminant Clostridium difficile Colitis During an Epidemic Caused by a Hypervirulent Strain , 2007, Annals of surgery.

[9]  C. Sirio,et al.  Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications , 2002, Annals of surgery.

[10]  M. Samore,et al.  Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. , 1996, The American journal of medicine.

[11]  E. Kuijper,et al.  Emergence of reduced susceptibility to metronidazole in Clostridium difficile. , 2008, The Journal of antimicrobial chemotherapy.

[12]  M. Rupnik,et al.  Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease? , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  C. Pothoulakis.  Effects of Clostridium difficile Toxins on Epithelial Cell Barrier , 2000, Annals of the New York Academy of Sciences.

[14]  A. Sonenshein,et al.  Repression of Clostridium difficile toxin gene expression by CodY , 2007, Molecular microbiology.

[15]  S. Weese,et al.  Prevalence of PCR Ribotypes among Clostridium difficile Isolates from Pigs, Calves, and Other Species , 2007, Journal of Clinical Microbiology.

[16]  T. Peláez,et al.  Metronidazole Resistance in Clostridium difficile Is Heterogeneous , 2008, Journal of Clinical Microbiology.

[17]  C. Pothoulakis,et al.  gp96 Is a Human Colonocyte Plasma Membrane Binding Protein for Clostridium difficile Toxin A , 2008, Infection and Immunity.

[18]  P. Edison,et al.  Clostridium difficile associated diarrhoea: how good are nurses at identifying the disease? , 2002, Age and ageing.

[19]  M. Rupnik,et al.  Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. , 2000, FEMS microbiology letters.

[20]  J. Rosenblatt,et al.  Comparison of Real-Time PCR for Detection of the tcdC Gene with Four Toxin Immunoassays and Culture in Diagnosis of Clostridium difficile Infection , 2008, Journal of Clinical Microbiology.

[21]  K. Owens,et al.  Cross-Contamination of Clostridium difficile Spores on Bed Linen During Laundering , 2007 .

[22]  C. Kelly,et al.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. , 2000, The New England journal of medicine.

[23]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[24]  B. Dupuy,et al.  Clostridium difficile toxin synthesis is negatively regulated by TcdC. , 2008, Journal of medical microbiology.

[25]  A. Barkun,et al.  Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection , 2008, Canadian Medical Association Journal.

[26]  M. Wilcox,et al.  Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. , 2003, The Journal of hospital infection.

[27]  B. Wee,et al.  Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. , 2001, Journal of medical microbiology.

[28]  Jane W. Marsh,et al.  Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  P. Boquet,et al.  Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins. , 1996, Trends in microbiology.

[30]  K. Aktories,et al.  Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. , 2007, Glycobiology.

[31]  J. Bartlett.  Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Wilcox,et al.  Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. , 2008, The Journal of antimicrobial chemotherapy.

[33]  M. Dionne,et al.  A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  R Sedivy,et al.  Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. , 1995, The Journal of clinical investigation.

[35]  D. Allen,et al.  Binary Toxin Production in Clostridium difficile Is Regulated by CdtR, a LytTR Family Response Regulator , 2007, Journal of bacteriology.

[36]  Julian Parkhill,et al.  The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome , 2006, Nature Genetics.

[37]  S. Michie,et al.  Interventions to improve antibiotic prescribing practices for hospital inpatients. , 2017, The Cochrane database of systematic reviews.

[38]  J. Plouffe,et al.  Treatment of Clostridium difficile colitis and diarrhea with vancomycin. , 1981, The American journal of medicine.

[39]  Klaus Aktories,et al.  Auto-catalytic Cleavage of Clostridium difficile Toxins A and B Depends on Cysteine Protease Activity* , 2007, Journal of Biological Chemistry.

[40]  M. Samore,et al.  Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. , 1999, The New England journal of medicine.

[41]  K. Saum,et al.  Effects of Clostridium difficile toxins given intragastrically to animals , 1985, Infection and immunity.

[42]  C. Kelly,et al.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea , 2001, The Lancet.

[43]  R. Gaynes,et al.  Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  N. Fairweather,et al.  Patterns of Sequence Conservation in the S-Layer Proteins and Related Sequences in Clostridium difficile , 2002, Journal of bacteriology.

[45]  M. Wilcox,et al.  Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. , 2004, The Journal of antimicrobial chemotherapy.

[46]  J. Songer,et al.  The Comparative Pathology of Clostridium difficile-associated Disease , 2006, Veterinary pathology.

[47]  K. Carroll,et al.  Effective Detection of Toxigenic Clostridium difficile by a Two-Step Algorithm Including Tests for Antigen and Cytotoxin , 2006, Journal of Clinical Microbiology.

[48]  J. Stockman.  A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile—Associated Diarrhea With High Morbidity and Mortality , 2007 .

[49]  M. Wilcox,et al.  Hospital disinfectants and spore formation by Clostridium difficile , 2000, The Lancet.

[50]  S. Péchiné,et al.  Variability of Clostridium difficile Surface Proteins and Specific Serum Antibody Response in Patients with Clostridium difficile-Associated Disease , 2005, Journal of Clinical Microbiology.

[51]  Julian I. Rood,et al.  Toxin B is essential for virulence of Clostridium difficile , 2009, Nature.

[52]  M. Wilcox,et al.  Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. , 2009, The Journal of antimicrobial chemotherapy.

[53]  W. Stamm,et al.  Nosocomial acquisition of Clostridium difficile infection , 1990 .

[54]  D. Gerding,et al.  PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.

[55]  C. Ramsay,et al.  Systematic Review of Antimicrobial Drug Prescribing in Hospitals , 2006, Emerging infectious diseases.

[56]  J. Gerberding,et al.  Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005. , 2005, MMWR. Morbidity and mortality weekly report.

[57]  B. Greene,et al.  12 MONTH FOLLOW-UP OF MEBENDAZOLE THERAPY FOR ONCHOCERCIASIS , 1981, The Lancet.

[58]  M. Mann,et al.  Glucosylation of Rho proteins by Clostridium difficile toxin B , 1995, Nature.

[59]  B. Dupuy,et al.  Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Jane W. Marsh,et al.  tcdC Genotypes Associated with Severe TcdC Truncation in an Epidemic Clone and Other Strains of Clostridium difficile , 2006, Journal of Clinical Microbiology.

[61]  J. Corver,et al.  Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  M. Wilcox,et al.  Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. , 2005, The Journal of antimicrobial chemotherapy.

[63]  Richard Holliman,et al.  Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. , 2008, The Lancet. Infectious diseases.

[64]  E. Kuijper,et al.  Use of Highly Discriminatory Fingerprinting to Analyze Clusters of Clostridium difficile Infection Cases Due to Epidemic Ribotype 027 Strains , 2008, Journal of Clinical Microbiology.

[65]  J. Brazier,et al.  The distribution of Clostridium difficile in the environment of South Wales. , 1996, Journal of medical microbiology.

[66]  J. Bakken,et al.  Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  D. Gerding,et al.  Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. , 2003, The Journal of infectious diseases.

[68]  J. Bartlett,et al.  Clinical recognition and diagnosis of Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  J. Ballard,et al.  Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication , 2006, Proceedings of the National Academy of Sciences.

[70]  S. Burdette,et al.  Does the nose know? The odiferous diagnosis of Clostridium difficile-associated diarrhea. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  B. Dupuy,et al.  Clostridium difficile toxin expression is inhibited by the novel regulator TcdC , 2007, Molecular microbiology.

[72]  M. Shimizu,et al.  A novel toxin homologous to large clostridial cytotoxins found in culture supernatant of Clostridium perfringens type C. , 2007, Microbiology.

[73]  L. Peterson,et al.  Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. , 1989, The Journal of infectious diseases.

[74]  M. Weidmann,et al.  Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. , 1997, European journal of biochemistry.

[75]  S. Tenzer,et al.  Autocatalytic cleavage of Clostridium difficile toxin B , 2007, Nature.

[76]  Carlene A. Muto,et al.  A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use , 2005, Infection Control & Hospital Epidemiology.

[77]  J. Heap,et al.  The ClosTron: a universal gene knock-out system for the genus Clostridium. , 2007, Journal of microbiological methods.

[78]  G. Corthier,et al.  Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196 , 1997, Infection and immunity.

[79]  L. Valiquette,et al.  Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  M. Wilcox,et al.  Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model , 2008, Antimicrobial Agents and Chemotherapy.

[81]  E. Chaves-Olarte,et al.  Cytotoxic effects of the Clostridium difficile toxins. , 2000, Current topics in microbiology and immunology.

[82]  C. Woods,et al.  Comparison of Seven Techniques for Typing International Epidemic Strains of Clostridium difficile: Restriction Endonuclease Analysis, Pulsed-Field Gel Electrophoresis, PCR-Ribotyping, Multilocus Sequence Typing, Multilocus Variable-Number Tandem-Repeat Analysis, Amplified Fragment Length Polymorphis , 2007, Journal of Clinical Microbiology.

[83]  M. Cerquetti,et al.  Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. , 2006, Microbes and infection.

[84]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[85]  C. R. Palmer.  Response to Article. , 1970 .

[86]  F. Nogareda,et al.  Rates of Clostridium difficile Infection in Patients Discharged From Spanish Hospitals, 1997-2005 , 2008, Infection Control & Hospital Epidemiology.

[87]  L. Lanthier,et al.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  Les Dethlefsen,et al.  The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing , 2008, PLoS biology.

[89]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[90]  D. Gerding,et al.  Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. , 2003, Anaerobe.

[91]  R. Platt,et al.  Epidemiology of community-acquired Clostridium difficile-associated diarrhea. , 1994, The Journal of infectious diseases.

[92]  J. Weese,et al.  Clostridium difficile in Retail Ground Meat, Canada , 2007, Emerging infectious diseases.

[93]  C. Donskey,et al.  Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[94]  M. Hu,et al.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. , 2009, Gastroenterology.

[95]  T. Eckmanns,et al.  Clostridium difficile Surveillance Trends, Saxony, Germany , 2008, Emerging infectious diseases.

[96]  L. Mcfarland.  Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease , 2006, The American Journal of Gastroenterology.

[97]  A. Widmer,et al.  Clostridium difficile Toxinotype V, Ribotype 078, in Animals and Humans , 2008, Journal of Clinical Microbiology.

[98]  D. Gerding,et al.  Toxinotype V Clostridium difficile in Humans and Food Animals , 2008, Emerging infectious diseases.

[99]  J. Vázquez-Boland,et al.  The Comprehensive Sourcebook of Bacterial Protein Toxins , 2006 .

[100]  N. Fairweather,et al.  Proteomic analysis of cell surface proteins from Clostridium difficile , 2005, Proteomics.

[101]  E. Kuijper,et al.  Emergence of Clostridium difficile-associated disease in North America and Europe. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[102]  T. Louie,et al.  Clostridium difficile Infections in a Canadian Tertiary Care Hospital before and during a Regional Epidemic Associated with the BI/NAP1/027 Strain , 2008, Antimicrobial Agents and Chemotherapy.

[103]  J. Songer,et al.  Clostridium difficile: an important pathogen of food animals. , 2006, Anaerobe.

[104]  P. Polgreen,et al.  Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. , 2008, American journal of obstetrics and gynecology.

[105]  M. Wilcox.  Diagnosis of Clostridium difficile-associated diarrhea and odor. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[106]  B. Limbago,et al.  Clostridium difficile in Retail Meat Products, USA, 2007 , 2009, Emerging infectious diseases.

[107]  Melinda B Davis,et al.  A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[108]  R. C. Parente,et al.  Cohort and Case-Control Studies in the Evidence-Based Medicine Era , 2011 .

[109]  C. von Eichel-Streiber,et al.  Increased number of Clostridium difficile infections and prevalence of Clostridium difficile PCR ribotype 001 in southern Germany. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[110]  M. Delmée,et al.  A Novel Toxinotyping Scheme and Correlation of Toxinotypes with Serogroups of Clostridium difficileIsolates , 1998, Journal of Clinical Microbiology.

[111]  T. Riley,et al.  Relapse versus reinfection with Clostridium difficile , 1991, Epidemiology and Infection.

[112]  D. Antonopoulos,et al.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. , 2008, The Journal of infectious diseases.

[113]  N. Fairweather,et al.  Human antibody response to surface layer proteins in Clostridium difficile infection. , 2004, FEMS immunology and medical microbiology.

[114]  T. Hundsberger,et al.  Definition of the single integration site of the pathogenicity locus in Clostridium difficile. , 1996, Gene.

[115]  M. Samore,et al.  Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea , 1998, The Lancet.

[116]  M. Wilcox,et al.  Efficacy of Hospital Cleaning Agents and Germicides Against Epidemic Clostridium difficile Strains , 2007, Infection Control & Hospital Epidemiology.

[117]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[118]  S. Lewis.  Response to the article: McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic-associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-22. , 2007, The American journal of gastroenterology.

[119]  J. Mossong,et al.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[120]  D. Gerding,et al.  Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile , 2008, Antimicrobial Agents and Chemotherapy.

[121]  J. Jernigan,et al.  A Randomized Crossover Study of Disposable Thermometers for Prevention of Clostridium difficile and Other Nosocomial Infections , 1998, Infection Control & Hospital Epidemiology.

[122]  J. Brophy,et al.  Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review , 2005, Canadian Medical Association Journal.

[123]  L. Peterson,et al.  Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. , 1990, The American journal of medicine.

[124]  N. Schupf,et al.  Reduction in Vancomycin-Resistant Enterococcus and Clostridium Difficile Infections Following Change to Tympanic Thermometers , 1998, Infection Control & Hospital Epidemiology.